hrs-6209
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2023 (NCT05781048)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06974929 | Phase 1/Phase 2 (Phase 2) | May 22, 2025 | Hengrui Therapeutics, Inc. |
| NCT06679036 | Phase 1/Phase 2 (Phase 2) | Nov 25, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06555068 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2024 | Hengrui Therapeutics, Inc. |
| NCT05781048 | Phase 1 | Apr 30, 2023 | Hengrui Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2023 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1